Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis.

Blood
J N BarkerJ E Wagner

Abstract

Umbilical cord blood (UCB) is being increasingly used for hematopoietic stem cell transplantation and has been associated with a reduced incidence of severe graft-versus-host disease (GVHD). To further investigate the relative merits of unrelated donor UCB versus bone marrow (BM), a matched-pair analysis comparing the outcomes of recipients of 0 to 3 human leukocyte antigen (HLA)-mismatched UCB and HLA-A, B, DRB1-matched BM was performed. UCB patients, who received cyclosporine (CSA) and methylprednisolone (MP), were matched for age, diagnosis, and disease stage with BM patients, who received either methotrexate (MTX) and CSA (26 pairs) or T-cell depletion (TCD) and CSA/MP (31 pairs). Patients were predominantly children (median age, 5 years) undergoing transplantation for malignancy, storage diseases, BM failure, and immunodeficiency syndromes between 1991 and 1999. Although neutrophil recovery was significantly slower after UCB transplantation, the probability of donor-derived engraftment at day 45 was 88% in UCB versus 96% in BM-MTX recipients (P =.41) and 85% in UCB versus 90% in BM-TCD recipients (P =.32), respectively. Platelet recovery was similar in UCB versus BM pairs. Furthermore, incidences of acute and chronic GVHD ...Continue Reading

References

Aug 1, 1980·The American Journal of Medicine·H M ShulmanE D Thomas
Jul 18, 1996·The New England Journal of Medicine·J KurtzbergP Rubinstein
Apr 1, 1996·Journal of Hematotherapy·M G RoncaroloJ Wagner
Nov 14, 1997·Current Opinion in Hematology·D L Confer
Nov 26, 1998·The New England Journal of Medicine·P RubinsteinC E Stevens
Dec 14, 1999·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·E D Thomas, K G Blume

❮ Previous
Next ❯

Citations

Sep 7, 2002·International Journal of Hematology·Hitomi NagayamaAsano Shigetaka
Nov 19, 2004·Springer Seminars in Immunopathology·Eliane Gluckman, Vanderson Rocha
Dec 4, 2010·Immunologic Research·Paul Szabolcs
Aug 22, 2009·International Journal of Hematology·Sofia BerglundJonas Mattsson
Jun 7, 2005·Human Immunology·M Brigid Bradley, Mitchell S Cairo
Jun 9, 2004·Blood Reviews·Yossi Cohen, Arnon Nagler
Oct 31, 2003·Critical Reviews in Oncology/hematology·Juliet N Barker, John E Wagner
Jul 24, 2008·Bone Marrow Transplantation·E GluckmanUNKNOWN Eurocord
Oct 6, 2009·Bone Marrow Transplantation·C G Brunstein, D J Weisdorf
Oct 6, 2009·Bone Marrow Transplantation·V K Prasad, J Kurtzberg
Oct 6, 2009·Bone Marrow Transplantation·V RochaE Gluckman
Jul 2, 2003·Nature Reviews. Cancer·Juliet N Barker, John E Wagner
May 26, 2012·Nature Reviews. Immunology·Hao Wei Li, Megan Sykes
Oct 31, 2007·Bone Marrow Transplantation·V Bachanova, D Weisdorf
Dec 18, 2007·Bone Marrow Transplantation·C Díaz de HerediaJ Sánchez de Toledo
Dec 18, 2007·Bone Marrow Transplantation·V Rocha, F Locatelli
Feb 5, 2008·Bone Marrow Transplantation·W W TseM J Laughlin
Jan 7, 2003·Internal Medicine Journal·I D Lewis
Mar 16, 2002·Transfusion·Rosemary L SparrowMark A Kirkland
Apr 23, 2005·Seminars in Hematology·Eliane GluckmanVanderson Rocha
Nov 27, 2004·The New England Journal of Medicine·Miguel A Sanz
Nov 27, 2004·The New England Journal of Medicine·Mary J LaughlinMary M Horowitz
Nov 27, 2004·The New England Journal of Medicine·Vanderson RochaUNKNOWN Eurocord-Netcord Registry
Aug 25, 2011·Stem Cells and Development·Michael UhlinJonas Mattsson
Nov 11, 2009·British Medical Bulletin·Anskar Y H Leung, Yok-Lam Kwong
Mar 7, 2002·Current Opinion in Oncology·Juliet N Barker, John E Wagner
Nov 19, 2004·Current Opinion in Hematology·Vanderson RochaUNKNOWN Eurocord and European Blood and Marrow Transplant Group
May 17, 2003·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Scott A HagenIra M Cheifetz
Jul 9, 2005·Transplantation·Yukiko KishiUNKNOWN Tokyo Stem Cell Transplant Consortium
Nov 23, 2010·JAAPA : Official Journal of the American Academy of Physician Assistants·Patsy Lynn SkablaJames Hampton
Feb 25, 2010·Current Opinion in Oncology·Maricer P Escalón, Krishna V Komanduri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.